Allergy Therapeutics
Positive top line G309 results for Grass MATA MPLAllergy Therapeutics
FY21 results show continued strong growthAllergy Therapeutics
VLP Peanut heading towards US Phase I studiesAllergy Therapeutics
Biomarker data confirm VLP Peanut hypoallergenicityAllergy Therapeutics
Strong FY21 trading, but pipeline set to drive futureAllergy Therapeutics
FY21 pre-close update ahead of market expectationsAllergy Therapeutics
G309 exploratory grass trial on course for H221 read-outAllergy Therapeutics
Record revenues demonstrate resilience of operationsAllergy Therapeutics
Robust growth, pipeline progress, and cash positionAllergy Therapeutics
Imperial peanut allergy biomarker study underway